Considering the amount of time it takes me to research all the 8K's and build the data into my spreadsheets, I prefer not to just hand out the information; I will provide a short summary though.
Total price of all acquisitions announced = $245,787,759
Total Cash payments = $102,470,927
Total Shares to be issued = 33,190,073
Projected annual revenues from acquisitions = $215,626,136
There is a void in information relating to the Medpharm/Medicine Man acquisitions; I haven't found it yet anyway. I have assumed a $50m price tag based upon a 1.25x multiple of the low end $40m in estimated annual revenue. The Cash payments/shares to be issued information does not include this acquisition since I haven't found a breakdown on it yet; will update after numbers are announced.
Keep in mind that some of the cash payments will be made over time with several of the acquisitions having an upfront payment then 12 month terms on the rest. Using Starbuds as an example; of the total cash payment, $15,502,544 is upfront while $7,751,272 is payable over the 12 months following the acquisition.
The share issuance also has some variables as well. The big thing to keep in mind with the shares is that portions of the issuance (not all) will have trading restrictions built into them. Even though the Outstanding share count will rise quickly, the Float (what is actually trade-able) should not go up significantly until the restrictions are lifted (usually after 1 year holding period). The Float remaining low will keep the volatility high and increases the chance of a large run when the "Herd" figures out that MDCL is the best in the industry.
Hope this helps,
Buy-Hold-Retire before your old,
Knife
News 
Market Data 
Discover 
